News from oxford biomedica plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

09 May, 2013, 09:00 BST Oxford BioMedica Announces Update from ARVO 2013

-- UshStat® video selected to showcase theme of "Life-changing Research" -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB),...


08 Aug, 2012, 08:00 BST Oxford BioMedica Announces Positive DSMB Review of Ongoing RetinoStat® and StarGen™ Clinical Studies

-- Treatment of final RetinoStat® patient cohort underway -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading...


23 Jul, 2012, 07:00 BST Oxford BioMedica Receives Funding Award from the Foundation Fighting Blindness for ongoing UshStat® Phase I/IIa study

-- Award of US$125,000 will support a second clinical site in Paris, France -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), ...


10 Jul, 2012, 07:00 BST Oxford BioMedica Announces Initiation of Phase II Collaborative Study for TroVax® in Colorectal Cancer

-- First patient treated at Cardiff University, Wales (UK) -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading...


31 Oct, 2011, 07:00 GMT Oxford BioMedica Announces Research and Development Collaboration for Glaucoma

- Research and development agreement signed with Mayo Clinic - Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading...


18 Oct, 2011, 07:00 BST Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B

-- Third ocular product partnered with Sanofi approved to enter clinical development -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company")...


22 Jun, 2011, 07:00 BST Oxford BioMedica Announces Ocular Programme Update

-RetinoStat® Progress in Phase I Study in Wet Age-Related Macular Degeneration Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), ...


23 May, 2011, 07:00 BST Oxford BioMedica Announces Presentation of New Clinical Data From ProSavin(R) Phase I/II Study in Parkinson's Disease

Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, announces that new data from the on-going...


15 Mar, 2011, 07:00 GMT Oxford Biomedica Announces Publication of TroVax(R) Phase III Analyses in Cancer Immunology, Immunotherapy

- Immune Response Surrogate Algorithm Shownto be a Significant Predictor of Clinical Benefit Oxford BioMedica plc ("Oxford BioMedica" or "the...